Statement of Principles concerning polymyalgia rheumatica (Reasonable Hypothesis) (No. 5 of 2025)

Administered by Department of Veterans' Affairs

Legislation au F2024L01698 In force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

STATEMENT OF PRINCIPLES CONCERNING

POLYMYALGIA RHEUMATICA

(REASONABLE HYPOTHESIS) (NO. 5 OF 2025)

 

VETERANS' ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

  1.              This is the Explanatory Statement to the Statement of Principles concerning polymyalgia rheumatica (Reasonable Hypothesis) (No. 5 of 2025).

Background

  1.              The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), repeals Instrument No. 19 of 2016 (Federal Register of Legislation No. F2016L00249) determined under subsection 196B(2) of the VEA concerning polymyalgia rheumatica.
  2.              The Authority is of the view that there is sound medical-scientific evidence that indicates that polymyalgia rheumatica and death from polymyalgia rheumatica can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(2) of the VEA a Statement of Principles concerning polymyalgia rheumatica (Reasonable Hypothesis) (No. 5 of 2025).  This Instrument will in effect replace the repealed Statement of Principles.

Purpose and Operation

  1.              The Statement of Principles will be applied in determining claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).
  2.              The Statement of Principles sets out the factors that must as a minimum exist, and which of those factors must be related to the following kinds of service rendered by a person:

 operational service under the VEA;

 peacekeeping service under the VEA;

 hazardous service under the VEA;

 British nuclear test defence service under the VEA;

 warlike service under the MRCA;

 non-warlike service under the MRCA,

before it can be said that a reasonable hypothesis has been raised connecting polymyalgia rheumatica or death from polymyalgia rheumatica, with the circumstances of that service.  The Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

  1.              This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 7 November 2023 concerning polymyalgia rheumatica in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.
  2.              The contents of this Instrument are in similar terms as the repealed Instrument.  Comparing this Instrument and the repealed Instrument, the differences include:
  • specifying a day of commencement for the Instrument in section 2;
  • revising the definition of 'polymyalgia rheumatica' in subsection 7(2);
  • revising the reference to 'ICD-10-AM code' in subsection 7(4);
  • new factor in subsection 9(1) concerning being treated with immune checkpoint inhibitors; and
  • new factor in subsection 9(2) concerning having a COVID-19 vaccine.

Consultation

  1.              Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to polymyalgia rheumatica in the Government Notices Gazette of 7 November 2023, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, the Military Rehabilitation and Compensation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority in relation to the investigation.

Human Rights

  1.              This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.  A Statement of Compatibility with Human Rights follows.

Finalisation of Investigation

  1.          The determining of this Instrument finalises the investigation in relation to polymyalgia rheumatica as advertised in the Government Notices Gazette of 7 November 2023.

References

  1.          A list of references relating to the above condition is available on the Authority's website at: www.rma.gov.au. Any other document referred to in this Statement of Principles is available on request to the Repatriation Medical Authority at the following address:

              

Email:    info@rma.gov.au

Post:      The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001


Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 5 of 2025

Kind of Injury, Disease or Death: Polymyalgia rheumatica

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(2) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).  Part XIA of the VEA requires the determination of these instruments outlining the factors connecting particular kinds of injury, disease or death with service such being determined solely on the available sound medical-scientific evidence.

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission and the Military Rehabilitation and Compensation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have polymyalgia rheumatica;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must as a minimum exist, before it can be said that a reasonable hypothesis has been raised, connecting polymyalgia rheumatica with the circumstances of eligible service rendered by a person, as set out in clause 5 of the Explanatory Statement;
  • replaces Instrument No. 19 of 2016; and
  • reflects developments in the available sound medical-scientific evidence concerning polymyalgia rheumatica which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICESCR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICESCR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members;
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD); and
  • ensuring that those rights "will be exercised without discrimination of any kind as to race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status" (Art 2, ICESCR).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Statement of Principles concerning polymyalgia rheumatica (Reasonable Hypothesis) (No. 5 of 2025) is an instrument determined under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). This instrument was enacted to address the issue of polymyalgia rheumatica in veterans and Defence Force members, facilitating the process for making claims and assessing eligibility for benefits. The Repatriation Medical Authority, pursuant to subsection 196B(2) of the VEA, repealed the previous Statement of Principles concerning polymyalgia rheumatica (Instrument No. 19 of 2016) and replaced it with this new instrument, reflecting updated medical-scientific evidence. This new Statement of Principles outlines the necessary factors to be considered when raising a reasonable hypothesis that polymyalgia rheumatica is related to specific types of service. The objective of this instrument is to ensure that claimants and relevant authorities have a clear understanding of the criteria and processes involved in claims related to polymyalgia rheumatica, thereby promoting fairness and transparency in the assessment and compensation of veterans' entitlements. The instrument has been designed to be compatible with human rights as recognised in international instruments, ensuring that it does not derogate from any human rights and promotes the rights of veterans, current and former Defence Force members, and their dependents. This includes facilitating access to social security and ensuring the right to an adequate standard of living, as well as the right to the highest attainable standard of physical and mental health. By replacing the previous instrument with updated medical-scientific evidence, this Statement of Principles aims to improve the quality of medico-scientific outcomes under the VEA and the MRCA, thereby better serving the needs of those affected by polymyalgia rheumatica.

Scope and Application

The Statement of Principles concerning polymyalgia rheumatica (Reasonable Hypothesis) (No. 5 of 2025) applies to veterans and current or former members of the Defence Force who are making claims under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. The Act specifies the circumstances in which a reasonable hypothesis can be raised that polymyalgia rheumatica or death from polymyalgia rheumatica is related to particular kinds of service, including operational, peacekeeping, hazardous, British nuclear test defence, warlike, and non-warlike service. This determination is made on the basis of available sound medical-scientific evidence. The legislation applies to individuals who have served in the Defence Force and are seeking compensation or medical treatment related to polymyalgia rheumatica. The Statement of Principles is designed to facilitate the assessment of claims by outlining the necessary factors that must exist for a connection to be made between the condition and the service rendered. The Act specifies that the reasonable hypothesis must relate to service rendered before the determination of this Statement of Principles. The Authority, under the Veterans' Entitlements Act 1986, determined this instrument to replace the previous Statement of Principles, reflecting updated medical-scientific evidence. The legislation does not specify any exclusions, exemptions, or thresholds beyond those outlined in the principles themselves. Subordinate instruments may further extend or clarify the application of this Act as necessary.

Key Provisions

The main operative sections of the Statement of Principles concerning polymyalgia rheumatica (Reasonable Hypothesis) (No. 5 of 2025) outline the factors necessary to establish a reasonable hypothesis connecting polymyalgia rheumatica or death from polymyalgia rheumatica with specific kinds of service under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). These factors must be related to operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non-warlike service under the MRCA (Sections 5 and 9). This Instrument replaces the previously repealed Instrument No. 19 of 2016 and incorporates recent medical-scientific evidence. The determination of this Instrument facilitates claims and reviews related to polymyalgia rheumatica, ensuring that claimants and the relevant Commissions have clear guidelines to follow. The Statement of Principles imposes specific obligations on claimants, the Repatriation Commission, and the Military Rehabilitation and Compensation Commission. Claimants must demonstrate that their polymyalgia rheumatica is connected to their service under the specified conditions outlined in the Instrument. The Commissions are required to assess claims based on the factors set out in the Statement of Principles, ensuring that the assessment process is transparent and evidence-based. Furthermore, the Veterans' Review Board and the Administrative Appeals Tribunal must review decisions in accordance with the criteria established by this Instrument. Breach of the provisions outlined in the Statement of Principles does not specifically detail offences, penalties, or civil/criminal consequences. However, non-compliance with the requirements for claims and assessments could result in the denial of benefits or compensation. The Act and related legislation may impose administrative penalties or other consequences for misrepresentation or fraudulent claims, although these are not explicitly detailed in the Statement of Principles. The focus of this Instrument is to ensure that claims are assessed fairly and based on sound medical-scientific evidence.

Legal classification tags

Area of Law
Veterans' Law
Instrument
Statutory Instrument
Concepts
Definitions & Interpretation
Offence Provisions
Licensing & Registration
Catchwords
Polymyalgia Rheumatica

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.